Therapierefraktäres atopisches Ekzem - erfolgreiche Therapie mit Dupilumab: Refractory Atopic Eczema − Successful Therapy with Dupilumab

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

Abstract

Until recently, in contrast to psoriasis vulgaris, no biologics were available for the treatment of atopic dermatitis, therefore the therapeutic options, especially in severe cases and lack of response to the only approved systemic therapy with ciclosporin A, were very limited. Dupilumab was approved in January 2018 as the first biologic for the treatment of atopic dermatitis. This is a fully human monoclonal antibody to the alpha subunit of the interleukin (IL)-4 receptor, thereby inhibiting IL-4/IL-13 signaling pathways. Here we describe the case of a 46-year-old asian patient with severe refractory atopic dermatitis as well as with secondary diagnosed eosinophilic pustular folliculitis and the course of his disease under therapy with dupilumab.

Translated title of the contribution
Refractory Atopic Eczema - Successful Therapy with Dupilumab

Details

Original languageGerman
Pages (from-to)219-223
Number of pages5
JournalAktuelle Dermatologie
Volume45
Issue number5
Publication statusPublished - 2019
Peer-reviewedYes

External IDs

Scopus 85065875714
ORCID /0000-0001-7457-6481/work/142246228
ORCID /0000-0002-4411-3088/work/142246235
ORCID /0000-0002-8217-6872/work/142246398
ORCID /0000-0002-4330-1861/work/143074031

Keywords

Sustainable Development Goals

ASJC Scopus subject areas